What is Stress Hyperglycemia?
Stress hyperglycemia is transient hyperglycemia occurring in previously non-diabetic patients during acute illness or invasive procedures, defined by blood glucose levels ≥180 mg/dL (10 mmol/L), with glucose returning to normal (<126 mg/dL or 7 mmol/L) after resolution of the stressor in patients with HbA1c <6.5%. 1
Key Defining Characteristics
The condition represents an acute metabolic response rather than underlying diabetes. The critical distinguishing feature is reversibility—glucose levels normalize once the physiological stress resolves and any glucose-lowering treatment is withdrawn 1. This differentiates it from undiagnosed pre-existing diabetes, which can be clarified by measuring HbA1c levels 1.
Pathophysiological Mechanisms
The primary driver is peripheral insulin resistance, which independently predicts morbidity and mortality 1. This occurs through a cascade of stress-related changes:
- Hormonal surge: Glucagon, cortisol, and catecholamines are released during physiological stress
- Inflammatory mediators: Interleukin-1 and interleukin-6 contribute to insulin resistance 1
- Increased glucose production: Enhanced hepatic gluconeogenesis and glycogenolysis 1
- Impaired glucose clearance: Increased renal glucose reabsorption and decreased peripheral glucose uptake 1
- Lipid dysregulation: Elevated free fatty acids further worsen insulin resistance 1
This insulin resistance can persist for several days post-procedure, initially affecting insulin-dependent peripheral tissues 1. Prolonged fasting, blood loss, and immobilization during the perioperative period compound these metabolic derangements 1.
Clinical Context and Prevalence
Stress hyperglycemia occurs in 30-80% of patients depending on the type and severity of acute illness or surgery 1. The highest prevalence is seen in:
- Cardiac surgery (particularly with extracorporeal circulation)
- Trauma and extensive burns
- Sepsis
- Critical illness requiring ICU admission 1, 2
Aggravating Risk Factors
Beyond the primary stressor, several factors amplify the severity:
- Catecholamine infusions
- Corticosteroid administration
- Obesity
- Advanced age
- Hypothermia and hypoxia
- Cirrhosis 1
Clinical Consequences and Why It Matters
Stress hyperglycemia is not benign—it carries significant morbidity and mortality risk 3. The harmful effects include:
- Abolished ischemic preconditioning 1
- Endothelial dysfunction 1
- Impaired immune function: Decreased phagocytic activity of neutrophils 1
- Increased blood-brain barrier damage in cerebral ischemia 1
- Myocardial harm: Free fatty acid release damages cardiac tissue 1, 4
- Delayed wound healing: Increased protein catabolism 1
These effects stem from mitochondrial dysfunction in non-insulin-dependent cells where glucose transporters (GLUT-4) become over-expressed during stress 1.
Critical Distinction from Pre-existing Diabetes
Common pitfall: Many hospitalized patients have undiagnosed type 2 diabetes that becomes apparent during acute illness. In one study, 18% of screened inpatients had glucose >180 mg/dL, with hyperglycemia occurring in 40% of known diabetics and 6% of non-diabetics 1.
The key differentiator is HbA1c: Values <6.5% with glucose normalization after stress resolution confirm true stress hyperglycemia rather than undiagnosed diabetes 1. Interestingly, some evidence suggests patients with stress hyperglycemia may face higher risk of adverse outcomes than those with pre-existing diabetes 5, though this relationship is complex and varies by clinical context 6.
Management Implications
For critically ill adults, initiate insulin therapy when glucose persistently exceeds 180 mg/dL (two consecutive readings) 7. The stress hyperglycemia ratio (SHR)—which accounts for baseline glycemia—is emerging as a superior prognostic marker compared to absolute glucose values alone 8, 6, 9.
Post-recovery follow-up is essential: Patients who experience stress hyperglycemia remain at increased risk for developing type 2 diabetes and require ongoing surveillance 2, 3.